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Abstract
Worldwide, traumatic brain injury (TBI) kills or hospitalises overBackground: 
10 million people each year. Early intracranial bleeding is common after TBI,
increasing the risk of death and disability. Tranexamic acid reduces blood loss
in surgery and death due to bleeding in trauma patients with extra-cranial injury.
Early administration of tranexamic acid in TBI patients might limit intracranial
bleeding, reducing death and disability. The CRASH-3 trial aims to provide
evidence on the effect of tranexamic acid on death and disability in TBI
patients. We will randomly allocate about 13,000 TBI patients (approximately
10,000 within 3 hours of injury) to an intravenous infusion of tranexamic acid or
matching placebo in addition to usual care. This paper presents a protocol
update (version 2.1) and statistical analysis plan for the CRASH-3 trial.
The primary outcome is head injury death in hospital within 28 days ofResults: 
injury for patients treated within 3 hours of injury (deaths in patients treated after
3 hours will also be reported). Because there are reasons to expect that
tranexamic acid will be most effective in patients treated immediately after
injury and less effective with increasing delay, the effect in patients treated
within one hour of injury is of particular interest. Secondary outcomes are
all-cause and cause-specific mortality, vascular occlusive events, disability
based on the Disability Rating Scale and measures suggested by patient
representatives, seizures, neurosurgical intervention, neurosurgical blood loss,
days in intensive care and adverse events. Sub-group analyses will examine
the effect of tranexamic acid on head injury death stratified by time to treatment,
severity of TBI and baseline risk.
 The CRASH-3 trial will provide reliable evidence of theConclusion:
effectiveness and safety of tranexamic acid in patients with acute TBI.
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            Amendments from Version 1
The revised version has been updated in the light of the reviewers 
comments:
Specifically we have:
1. Explained in the abstract that we hope to have up to 10,000 
patients within 3 hours of injury.
2. Explained that the original sample size estimate was 10,000 
patients overall but that now we aim to have this many patients 
within 3 hours of injury.
3. Explained that means and SD will be presented for continuous 
baseline variables.
4. Explained that the primary analyses will present relative risks.
5. Acknowledged that time to treatment is estimated.
6. Explained where the data for the Figure came from.
7. Removed the sentence: "However, we hypothesise that the risk 
reduction with tranexamic acid would be greatest in patients at 
low risk of death since a smaller proportion of these patients will 
have un-survivable TBI." This was an error left over from an earlier 
version.
8. Laid out abbreviations and corrected minor typos. 
See referee reports
REVISED
List of abbreviations
AEs: Adverse events; CI: Confidence interval; CONSORT: 
Consolidated Standards of Reporting Trials; CRASH-2: Clinical 
randomisation of an anti-fibrinolytic in significant haemorrhage; 
CRASH-3: Clinical randomisation of an anti-fibrinolytic in 
significant head injury; CT: Computed tomography; DMP: Data 
Management Plan; DIC: Disseminated intravascular coagulation; 
GCS: Glasgow coma scale; HIV: Human immunodeficiency 
virus; ICH-GCP: International Conference on Harmoniza-
tion – Good Clinical Practice; IBMS: Intracranial Bleeding 
Mechanistic Sub-study; ICU: Intensive Care Unit; LSHTM: 
London School of Hygiene and Tropical Medicine; PAI-1: 
Plasminogen activator inhibitor-1; RR: Relative risk; SAEs: 
Serious adverse events; SUSARs: Suspected unexpected 
serious adverse reaction; TB: Tuberculosis; TBI: Traumatic brain 
injury; TPA: Tissue plasminogen activator; TXA: Tranexamic 
acid; UK: United Kingdom; USA: United States of America
Introduction
There are more deaths each year from injuries than from 
HIV, TB and malaria combined1. Worldwide, over ten million 
people are killed or hospitalised each year after traumatic brain 
injury (TBI)2. Road traffic crashes are the main cause of seri-
ous TBI. Most of the deaths are in low and middle income coun-
tries where the TBI incidence is high due to rapidly increasing 
motorisation3. Africa and South Asia have particularly high 
TBI rates, due to their high rate of traffic crashes3.
Early intracranial bleeding is common after TBI and increases 
the risk of death and disability4. In patients with moderate and 
severe TBI, intracranial bleeding may continue after hospital 
admission and for several hours after injury5–7. Abnormal 
coagulation with increased fibrinolysis may worsen intracranial 
bleeding8. High levels of fibrin degradation products are often 
seen in the first three hours9. These patients have a higher risk 
of intracranial bleeding and death.
Tranexamic acid reduces bleeding by inhibiting the enzymatic 
breakdown of fibrinogen and fibrin. A systematic review of 
randomized trials of tranexamic acid in surgery showed that 
tranexamic acid reduces blood loss by one third10. Tran-
examic acid also reduces mortality in bleeding trauma patients. 
In 2011, the CRASH-2 trial showed that administration of 
tranexamic acid to poly-trauma patients within three hours 
of injury reduces deaths due to bleeding by about one third11,12. 
In 2017, the WOMAN trial showed that administration of tran-
examic acid to women with post-partum haemorrhage within 
three hours of delivery reduces deaths due to bleeding by about 
one third13. Later in 2017, results from an individual patient-level 
data meta-analysis of randomised trials of tranexamic acid in 
acute severe bleeding showed that whilst immediate treatment 
substantially improves survival, the survival benefit decreases by 
around 10% for every 15 min of treatment delay until 3 h, after 
which there was no benefit14.
The CRASH-3 trial is an international, randomized, placebo- 
controlled trial to quantify the effects of early administra-
tion of tranexamic acid on death and disability in patients with 
TBI. We expect tranexamic acid to be more effective than 
placebo in reducing death and disability in patients with TBI. 
We published the protocol before the start of the trial15. In 
September 2016 we increased the sample size from 10,000 to 
13,000 patients. In this paper, we provide the reason for this 
increase. This statistical analysis plan was completed and submitted 
for publication before the treatment allocation was un-blinded.
Trial methods
Trial design and patients
The CRASH-3 trial is an international, multi-centre, randomised, 
parallel group, double blind, placebo controlled trial of the effects 
of early administration (within 3 hours of injury) of tranexamic 
acid on death and disability in TBI patients. Adults with TBI 
within 3 hours of injury, with any intracranial bleeding on CT 
scan or who have a GCS of 12 or less, and no significant extra 
cranial bleeding are potentially eligible. The time window for 
eligibility was originally within 8 hours of injury but in 2016 
the protocol was amended to limit recruitment to patients who 
are within 3 hours of injury. We will randomly allocate approxi-
mately 13,000 TBI patients who meet the eligibility criteria 
to receive tranexamic acid or placebo. The primary outcome 
is head injury death in hospital within 28 days of injury in 
patients treated within 3 hours of injury.
Trial registration
The CRASH-3 trial was prospectively registered at the Inter-
national Standard Randomised Controlled Trials registry 
(ISRCTN15088122) on 19 July 2011, and ClinicalTrials.gov on 
25 July 2011 (NCT01402882).
Ethics approval
The Medical Research and Ethics Committee and Health 
Research Authority reviewed the protocol and supporting 
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documents for the CRASH-3 trial and provided a favourable 
ethical opinion on 19 July 2012 (Research Ethics Committee 
Reference 12/EE/0274). The Medicines and Healthcare Products 
Regulatory Agency authorised the CRASH-3 trial on 8 August 
2012 (Reference 17072/0007/001-0001). Favourable ethical opin-
ion was received from the Observational/Interventions Research 
Ethics Committee at the London School of Hygiene and Tropical 
Medicine (LSHTM) on 17 November 2011 (Reference 6060). The 
Medical Research and Ethics Committee and Health Research 
Authority reviewed the protocol and supporting documents for the 
IBMS and provided a favourable ethical opinion on 8 June 2016 
(Research Ethics Committee Reference 12/EE/0274). Favourable 
ethical opinion was received from the Observational/Interventions 
Research Ethics Committee at the London School of 
Hygiene and Tropical Medicine on 24 May 2016 (Reference 
11535). Important protocol modifications to the CRASH-3 
trial will be submitted to and reviewed by the Medicines and 
Healthcare Products Regulatory Agency, Medical Research and 
Ethics Committee and Health Research Authority, and registries 
updated as appropriate. All ethical approvals have been reviewed 
in support of publication of the CRASH-3 trial protocols15,16.
Consent to participate
TBI patients are physically and mentally incapable of providing 
informed consent to participate in a clinical trial. As acknowl-
edged in the Declaration of Helsinki, patients who are incapable 
of giving consent are an exception to the general rule of informed 
consent in clinical trials (34). In the CRASH-3 trial, patients 
are unable to provide consent and so consent is sought from 
the patient’s relative, legal representative or the responsible 
clinician. If and when the patient regains capacity to provide 
informed consent, they are informed about the trial and written 
consent sought to continue their participation in the trial. If 
a patient or patient representative declines consent, they are 
withdrawn from the trial. For patients who were included in 
the trial but did not regain capacity, written informed consent is 
sought from a relative or legal representative. The requirements 
of relevant local and national ethics committees are adhered 
to at all times. The CRASH-3 trial includes consent to extract 
data from patient medical records. Collecting CT scan data for 
the IBMS is consistent with the consent procedure used in the 
CRASH-3 trial. It would be impractical to re-consent patients or 
relatives/legal representatives to access CT scans, particularly 
for patients who have deceased or are disabled as a result of 
their injuries where re-consent would be distressing and unwel-
come. LSHTM and national Ethics Committees extended their 
approvals to extract CT data from the CRASH-3 trial without 
further patient consent. Patients who withdrew from the main 
CRASH-3 trial would not be included in the IBMS.
Randomisation and masking
An independent statistical consultant from Sealed Envelope 
Ltd (UK) prepared and secured the randomisation codes. 
They were then given to the drug packers so that treatment 
packs could be prepared in accordance with the randomisation 
list. We will randomise TBI patients eligible for inclusion to 
receive active treatment (tranexamic acid) or placebo (sodium 
chloride, 0.9%) intravenously. Half of the patients will receive 
tranexamic acid whilst the other half will receive placebo. 
Baseline information will be collected on the entry form and 
the next lowest consecutively numbered pack will be taken 
from a box of eight treatment packs. If the treatment ampoule is 
confirmed as intact, the patient is considered randomised. Entry 
form data should be sent to the Trial Coordinating Centre as 
soon as possible. Both participants and study staff (site inves-
tigators and trial coordinating centre staff) will be masked to 
allocation. An emergency un-blinding service is available. The 
tranexamic acid (Cyklokapron® Injection) used in the trial 
is manufactured by Pfizer Ltd Sandwich (UK). The South 
Devon Healthcare NHS Trust (UK) manufacture the matching 
placebo (sodium chloride, 0.9%). Ampoules and packaging 
are identical in appearance. The blinding is done by Brecon 
Pharmaceuticals Limited (Hereford, UK). The blinding process 
involves removal of the original manufacturer’s label and 
replacement with the clinical trial label bearing the randomi-
sation number (the pack identification). All pack label texts 
are identical for both tranexamic and placebo. We check 
the coding of blinded ampoules by randomly testing each 
batch of trial treatments and doing high performance liquid 
chromatography to check the contents.
Trial procedures
When eligibility has been confirmed and the consent procedure 
followed, each patient is assigned a uniquely numbered treatment 
pack and are thus randomly allocated to receive tranexamic acid 
(loading dose 1g over 10 minutes followed by an infusion of 1g 
over 8 hours) or matching placebo. Once randomised, we will 
collect patient outcome data even if the trial treatment is not 
given. Outcome data are collected four weeks (28 days) after 
randomisation, at discharge from the randomising hospital or at 
death (whichever occurs first).
Sample size
We originally estimated that a trial with about 10,000 patients 
would have 90% power (two-sided alpha of 1%) to detect a 
15% relative reduction (20% to 17%) in mortality. However, 
whilst the trial was underway, new research suggested a shorter 
therapeutic window than 8 hours12,13. The new data showed that 
tranexamic acid is most likely to improve outcome if given soon 
after injury and would be unlikely to improve outcome if given 
beyond three hours of injury. In response to this evidence, in 
September 2016, we changed the primary outcome to head 
injury death in hospital within 28 days of injury in patients 
randomised within 3 hours of injury. We also limited recruitment 
to within 3 hours. We increased the sample size to 13,000 to 
get enough patients (about 10,000 as per the original sample 
size calculation) within 3 hours of injury to confirm or refute 
an early benefit. Statisticians at the London School of Hygiene 
and Tropical Medicine (University of London) have reviewed 
the sample size calculations.
Statistical analysis plan
Trial profile
We will show the flow of study participants in a Consolidated 
Standards of Reporting Trials (CONSORT) diagram. This will 
include the total number of participants randomised into the 
trial divided by treatment arm. Each treatment arm will detail 
the number of patients who withdrew consent, the number of 
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patients for whom baseline data was collected, the number lost 
to follow up and the number of patients for whom outcome data 
was collected. Because TBI is a life-threatening emergency, 
we do not ask clinicians to complete a screening log since this 
would take time away from important clinical work. We will 
report the number of patients included in the primary and second-
ary analyses, the reasons for any post-randomisation exclusions 
and the number lost to follow-up. We will count patients that did 
not fulfil the eligibility criteria or did not receive their allocated 
treatment as having deviated from the protocol. Their data 
will be included in the intention to treat analysis. If a patient 
or their representative withdraws consent for data collection, 
we will use only data up to the point of withdrawal in the analysis.
Baseline characteristics
The trial Entry Form (Supplementary File 1) will be used to 
collect baseline information including age, sex, time since 
injury, systolic blood pressure, Glasgow coma score, pupil 
reaction, and if relevant, the location of intracranial haemor-
rhage. To check that randomisation produced similar groups, 
we will describe the baseline characteristics of each group 
with frequencies, percentages, means, medians and standard 
deviations as appropriate. 
Primary outcome
The primary outcome is head injury death in hospital within 
28 days of injury among patients randomised within 3 hours 
of injury. Because there are strong scientific reasons to expect 
that tranexamic acid will be most effective in patients treated 
within an hour of injury and less effective with increasing treat-
ment delay, the effect in patients treated within one hour of 
injury is of particular interest. Cause of death is assessed and 
recorded by the responsible clinician. Although some misclassifi-
cation is inevitable, all-cause mortality combines causes of death 
that might be affected by tranexamic acid (e.g. head injury death) 
with causes that we do not expect to be affected by tranexamic 
acid (e.g. sepsis death) and this will dilute any effect.
In the original trial protocol, the primary end-point included 
all patients randomised within 8 hours of injury. This was 
based on the CRASH-2 trial results which showed that giving 
tranexamic acid to patients with traumatic extra-cranial bleeding 
within eight hours of injury reduces death due to bleeding and 
all-cause mortality11. However, pre-specified subgroup analyses 
showed that the effect of tranexamic acid depends on the time 
interval between the injury and start of treatment12. Treatment 
within three hours of injury substantially reduced death due 
to bleeding and all-cause mortality whereas treatment started 
after three hours appeared to increase death due to bleeding 
and had no effect on all-cause mortality. Although we expected 
early treatment to be most effective, we did not expect such a 
qualitative time to treatment interaction. It is unusual for a 
treatment to be beneficial in one subgroup and completely 
ineffective or harmful in another.
In response to the CRASH-2 trial results, research was 
conducted into the mechanism of action of tranexamic acid in 
trauma patients. This research provided a biological explanation 
for the time to treatment interaction. Early fibrinolysis is common 
after trauma and is associated with increased mortality17–19. 
Trauma triggers the early release of tissue plasminogen activator 
(TPA), the enzyme that converts plasminogen into the fibrino-
lytic enzyme plasmin20,21. Plasmin activation leads to fibrinolysis 
and profuse bleeding. TPA levels peak about 30 minutes after 
injury and plasmin levels peak around one hour21. By inhibiting 
early fibrinolysis, tranexamic acid prevents early exsanguination17. 
However, the effects are short lived. About two hours 
after injury, plasminogen activator inhibitor-1 (PAI-1) levels 
start to increase reaching a peak at three hours21. PAI-1 inhibits 
fibrinolysis22. This might explain why early tranexamic acid 
treatment is so important12. The adverse effects of late tran-
examic acid administration could be due to PAI-1-induced 
suppression of fibrinolysis and the onset of thrombotic dis-
seminated intravascular coagulation (DIC). By inhibiting 
fibrinolysis, tranexamic acid might worsen DIC. Although 
the pathology is thrombotic, due to consumption of clotting 
factors, thrombotic DIC usually manifests as bleeding. Because 
TBI patients show similar coagulation changes, a similar time to 
treatment interaction is possible23–25.
In 2016 we obtained results from the WOMAN trial of the effect 
of tranexamic acid on death due to bleeding after post-partum 
haemorrhage (the results were published in 2017). The WOMAN 
trial provided more evidence in support of a time to treatment 
interaction. Treatment within three hours significantly reduced 
death due to bleeding but there was no evidence of any ben-
efit beyond three hours13. In light of the accumulating evidence 
that tranexamic acid treatment is unlikely to be effective when 
started more than three hours after injury, in September 2016, 
we restricted CRASH-3 trial recruitment to patients within 3 hours 
of injury and changed the primary end point accordingly.
In 2017, we published an individual patient-level data meta- 
analysis of randomised trials of tranexamic acid in acute severe 
bleeding. The results showed that immediate treatment improved 
survival by more than 70% (OR 1·72, 95% CI 1·42–2·10; p<0·0001) 
but thereafter, the survival benefit decreased by about 10% for 
every 15 min of treatment delay until 3 hours, after which there 
was no benefit14. It is reasonable to expect a similar decline in 
treatment benefit in the context of acute intracranial bleeding. 
Because the treatment effect in patients treated within 3 hours 
of injury will be a weighted average of the effects in the first, 
second and third hours after injury, and most patients (about 
80%) are recruited in the second and third hours, the overall 
effect could be diluted towards the null. For this reason the effect 
of treatment in patients treated within an hour of injury is of 
particular scientific interest. It is important to bear in mind that if 
tranexamic acid is shown to be safe and effective, time to treat-
ment in clinical practice can be much shorter than in a clinical 
trial since there is no requirement for consent procedures and the 
treatment can be given earlier in the clinical pathway (e.g. 
pre-hospital).
In summary, although intracranial bleeding can continue up to 
24 hours after injury, research published since the start of the 
CRASH-3 trial showed that treatment started beyond 3 hours 
of injury is unlikely to be effective and that even within the first 
three hours, earlier treatment is more likely to be of benefit. For 
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these reasons, we changed the primary outcome to head injury 
death in patients randomised within 3 hours of injury with a 
focus on the effect in the first hour. All outcomes for patients 
treated after three hours of injury will be presented separately.
Primary analysis
The main analyses will compare those allocated tranexamic 
acid versus those allocated placebo, on an intention to treat 
basis (irrespective of whether they received the allocated treat-
ment). The primary analyses will be presented as relative 
risks and 95% confidence intervals. Kaplan-Meier estimates 
for the time to each of the primary and secondary outcomes 
will also be plotted (with their associated log-rank p-values).
Sensitivity analysis
TBI patients who have a GCS of 3 and bilateral un-reactive pupils 
have a very poor prognosis, with a mortality risk of about 75%. 
The inclusion in the CRASH-3 trial of such severely injured 
patients, who may have little potential to benefit from the trial 
treatment, would bias the treatment effect towards the null. 
We will therefore conduct a sensitivity analysis on the primary 
endpoint that excludes patients with a GCS 3 and bilateral 
unreactive pupils.
Missing data
Given the progress of data collection so far, we expect that loss 
to follow-up will be minimal (i.e. less than 1% missing data 
on the primary outcome) and so we will not impute missing 
values.
Sub-group analyses
We will define all subgroups according to variables measured 
before randomisation. We will carry out the following subgroup 
analyses for head injury deaths.
(a) Time to treatment
We expect that the effect of tranexamic acid on death from head 
injury will vary by time to treatment with earlier treatment being 
most effective. We will examine this hypothesis by conducting 
sub-group analysis of the effect of tranexamic acid according 
to the estimated time interval between injury and randomisation 
(≤1, >1–≤3, >3h). Because TBI severity (GCS and pupil response), 
SBP and age could confound the impact of time to treatment 
on treatment effectiveness (Figure 1), we will control for these 
variables in a multivariable model. Because there is prior evidence 
to expect a time to treatment interaction, we do not require as 
strong evidence against the null hypothesis of homogeneity 
Figure 1. Relationship between baseline prognostic variables (dilated pupils, GCS, blood pressure and age) and time to treatment in 
hours. Based on blinded data on approximately 10,000 patients from the CRASH-3 trial.
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as we might usually require. Most trials lack power to detect 
heterogeneity in treatment effects and the lack of a statistically 
significant interaction does not mean that the overall treat-
ment effect applies to all TBI patients. Because there is prior 
evidence that late treatment may be ineffective or harmful, we 
will consider the results of the time to treatment sub-group 
analysis in the context of the existing trial data (including data 
from the CRASH-2 trial) on the time to treatment interaction 
with tranexamic acid and rely more on scientific judgment than 
on statistical tests. Because missing data for time to treatment 
is minimal, only patients with time to treatment data will be 
included in the analyses.
(b) Severity of head injury
We will examine the effect of tranexamic acid on death from 
head injury stratified by the severity of TBI at baseline. We 
will examine three sub-groups: mild (GCS 13-15), moderate 
(GCS 9-12) and severe (GCS 3-8). We will use interaction 
tests to see whether the effect of the treatment (if any) differs 
across these subgroups. We will also assess the impact of base-
line severity on the treatment effect in a regression analysis that 
includes continuous terms for severity and its square (because of 
potential non-linearity of the treatment effect). Because time to 
treatment, SBP and age could confound impact of severity on 
treatment effectiveness, we will control for these variables. We 
do not expect the effect of tranexamic acid to vary substantially 
by severity of TBI and unless there is strong evidence against 
the null hypothesis of homogeneity of effects (i.e. p<0.001) the 
overall relative risk will be considered the most reliable guide to 
the approximate treatment effect in all patients.
(c) Age
There is evidence that fibrinolytic activation following TBI is 
greater in older patients26. For this reason, we will examine 
the effect of tranexamic acid on head injury death stratified 
by age. We will examine three age strata: young (<30 years), 
middle (31–60 years), older (>60 years). Because time to treat-
ment, TBI severity and SBP could confound the effect of age 
on treatment effectiveness, we will control for these variables. 
We will use interaction tests to see whether the effect of the 
treatment (if any) differs across these subgroups. We do not 
expect the effect of tranexamic acid to vary substantially by age 
and unless there is strong evidence against the null hypothesis 
of homogeneity of effects (i.e. p<0.001) the overall relative risk 
will be considered the most reliable guide to the approximate 
treatment effect in all patients.
Secondary outcomes
Early head injury death: Because early head injury deaths are 
more likely to be the result of intracranial haemorrhage (since 
bleeding occurs early) than late head injury deaths (these are 
more likely due to non-bleeding causes that are unaffected by 
TXA), we will examine the effect of TXA on head injury deaths 
within 48 hours and 7 days of randomisation.
Cause specific mortality: We will assess and report the effect 
of tranexamic acid on all-cause mortality and cause specific 
mortality using relative risks and 95% confidence intervals. 
We will also present the distribution of causes of death by days 
since randomisation.
Disability: We assess disability using the Disability Rating Scale 
and with a set of disability questions based on discussions with 
victim representatives. The Disability Rating Scale measures the 
level of disability in six diagnostic categories: (1) eye opening, 
(2) best verbal response, (3) best motor response, (4) self-care 
ability for feeding, grooming and toileting, (5) level of cognitive 
functioning, and (6) employability. We can use the Disability 
Rating Scale across the span of recovery. The maximum score a 
patient can obtain is 29, which represents an extreme vegeta-
tive state. A person without disability would score zero. We will 
assess the effect of tranexamic acid on disability by comparing 
the mean Disability Rating Scale score in the tranexamic acid 
and placebo groups using parametric and non-parametric tests. 
We will report the effect of tranexamic acid on the patient 
derived disability measure by estimating the risk ratio of being 
in the extreme categories for each of the six areas of function-
ing (1. walking, 2. washing, 3. pain and discomfort, 4. anxiety or 
depression, 5. agitation or aggression and 6. fatigue).
Vascular occlusive events: By inhibiting fibrinolysis, tranexamic 
acid could increase the risk of cerebral ischaemia and throm-
bosis. Cerebral ischaemia is a common pathophysiological 
mechanism after TBI that can worsen neurological outcome 
and increase mortality. Raised intracranial pressure could lead 
to cerebral hypo-perfusion and thrombotic DIC might increase 
the risk of the cerebral micro-thrombi. These thrombi are 
often found in autopsies of patients with severe TBI. We will 
assess and report the effect of tranexamic acid on the risk ratio 
for fatal and non-fatal stroke both overall and stratified by 
time to treatment (less than versus more than 3 hours). The 
effect of tranexamic acid on cerebral infarction will be further 
evaluated using routine brain imaging from a selection of trial 
patients (sub-study to be published separately). The effect of 
tranexamic acid on other vascular occlusive events (fatal and 
non-fatal myocardial infarction, deep vein thrombosis and pulmo-
nary embolism) will be reported both separately and combined.
Seizures: Tranexamic acid crosses the blood-brain barrier and 
in high dosages causes seizures. Although there was no increase 
in seizures in the CRASH-2 trial of tranexamic acid in extra-
cranial bleeding, seizure activity is more common after TBI 
and remains a concern. We will therefore report the effect of 
tranexamic acid on the risk ratio for seizures.
Neurosurgical interventions for intracranial haemorrhage: If 
tranexamic acid treatment reduces intracranial bleeding it might 
reduce neurosurgical intervention for bleeding. On the other 
hand, if neurosurgical intervention precedes or coincides with 
administration of the trial treatment, there will be no opportunity 
for tranexamic acid to have an effect. We expect that including 
such patients in the analysis will dilute the treatment effect 
towards the null. Although tranexamic acid might not have 
enough time to reduce the need for neurosurgical intervention in 
the first place, it should have enough time to reduce the amount 
of bleeding during the operation. We will report the effect of 
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tranexamic acid on haematoma evacuation and the mean blood 
loss in tranexamic acid and placebo treated patients. We will 
test the effect of treatment allocation on haematoma evacuation 
using relative risks and 95% confidence intervals. We will test 
the effect of treatment allocation on mean blood loss using a 
two-sample t-test.
Complications: Patients with TBI are at risk of other significant 
medical events including renal failure, sepsis and gastrointestinal 
bleeding and these outcomes are collected routinely.
Adverse events: We collect other untoward medical events up 
to 42 days after randomisation as adverse events (AEs). In line 
with ICH-GCP guidelines, an AE is considered as serious if 
it results in death, is life-threatening, requires inpatient hospi-
talisation or prolongation of existing hospitalisation, results in 
persistent or significant disability/incapacity, or in a congenital 
anomaly/birth defect16. If there is a possibility that an AE is due 
to the trial drug, it is an adverse reaction. A suspected unex-
pected serious adverse reaction (SUSAR) is an unexpected 
occurrence of a serious adverse reaction. There need only be an 
index of suspicion that the event is a previously unreported reac-
tion to a trial drug or a previously reported but exaggerated or 
unexpectedly frequent adverse drug reaction.
The number of AEs, SAEs, SUSARs grouped by MedDRA® 
codes and the number of patients with at least one event will be 
compared between arms using a chi-squared test (or Fisher’s 
exact test), with relative risks and 95% confidence intervals when 
these are computable.
Other analyses: to be reported in separate 
publications
Analysis 1. Reducing the impact of null bias
We will examine the timing of the effect of tranexamic acid on 
outcomes among patients treated within three hours of injury, by 
conducting repeated analyses excluding outcomes at increasing 
time intervals from randomisation. We will increase the length 
of the exclusion period by one hour at a time. This means that 
patients who die quickly following randomisation (who are 
more likely to have un-survivable injuries at baseline) can 
be excluded and the treatment effect evaluated without this 
null bias. Risk ratios and 95% confidence intervals will be 
estimated to assess the size and precision of the treatment effect.
Analysis 2: Adjusting for possible imbalance in baseline 
prognostic factors
Given the size of the CRASH-3 trial, baseline characteristics 
that may influence the outcome should be evenly distributed 
between the treatment and placebo groups, so that any difference 
in outcome can be attributed to the intervention. However, it 
is still possible that a chance imbalance in important prog-
nostic factors could influence the results. To investigate this 
possibility, we will conduct an analysis of the effect of treat-
ment that is adjusted for baseline risk. We will build a prognostic 
model based on pre-specified baseline variables and use it 
to estimate the predicted risk of the outcome at baseline.
The primary outcome is head injury death. The most important 
prognostic factors for this outcome that are measured at base-
line are age, GCS score, pupil reactivity and systolic blood 
pressure. These variables will be included in a multivariable 
prognostic model based on the final trial dataset. Although there 
are almost complete data on these variables, in the case of miss-
ing data, the missing values. The trial data will then be stratified 
into risk deciles as shown in the Table based on the predicted 
risk of the outcomes at baseline. We will report frequencies and 
percentages within each risk decile, and calculate a risk ratio 
(with 95% CI) for each risk decile. The pooled risk ratio (with 
a 95% CI) will be estimated as an inverse variance weighted 
average of the stratum specific risk ratios. The pooled risk 
ratio should provide an estimate of the treatment effect that is 
un-confounded by baseline risk. The advantage of this approach 
is that the effect of baseline risk on the treatment effect is more 
explicit than when covariate adjusted odds ratios are calculated 
using logistic regression. Furthermore, risk ratios are easier 
to interpret and apply to individual patients than are odds ratios.
A forest plot will be prepared to show graphically how the 
treatment effect varies by baseline risk. We will use a chi-squared 
test to assess any heterogeneity in treatment effect across the 
risk groups and we will calculate the I-squared statistic to quan-
tify the percentage of variability in effect estimates that is due 
to heterogeneity rather than chance. To reduce the likelihood 
of making inappropriate inferences, we pre-specify that unless 
there is strong evidence against the null hypothesis of homo-
geneity of effects (i.e. P<0.001), the pooled relative risk will be 
considered the most reliable guide to the approximate treatment 
effects in all risk strata. We do not anticipate substantial heteroge-
neity by baseline risk. 
Analysis 3: Cost effectiveness
An economic analysis will be relevant if tranexamic acid clearly 
demonstrates efficacy in achieving its clinical aims. In this case, 
the study will be undertaken in the form of a cost-effectiveness 
analysis with the aim of estimating the incremental cost- 
effectiveness ratio comparing the use of tranexamic acid with 
normal clinical practice. Analysis will be based on adjusted 
life years gained. A further analysis will explore the use of 
the EQ-5D data to quality-adjusted survival. In this study, the 
economic analysis is clearly bounded as virtually all significant 
resource use will occur in the initial period of hospitalisation. As 
such, neither a long-term resource analysis nor an analysis 
of out of hospital costs will be required. The trial use of tran-
examic acid is likely to mirror its use in normal clinical practice, 
hence the cost-effectiveness estimated in the trial (adjusted for 
protocol driven costs) will closely approximate cost-effectiveness 
in actual clinical practice. Data on physical resource consump-
tion (e.g. length and nature of hospital stay) will be collected 
for each patient and a common unit cost at a country level will 
be applied. A sensitivity analysis will be undertaken to assess 
the robustness of the economic analysis in response to vari-
ations in key variables such as drug prices. In all cases, the 
economic analysis will be integrated with the clinical trial 
procedures to optimise efficiency and minimise inconvenience 
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to patients. Time in the Intensive Care Unit (ICU) is the key 
resource consumption variable. Length of stay in the ICU and the 
hospital will be censored due to early deaths, or a stay in the ICU 
or hospital longer than 42 days. Summary statistics will include 
the median and the interquartile range computed separately 
for each treatment arm.
Analysis 4: Examining the mechanism of action of 
tranexamic acid in TBI
An Intracranial Bleeding Mechanistic Sub-Study (IBMS) is nested 
in a cohort of approximately 1,000 CRASH-3 trial patients. This 
sub-study aims to examine the mechanism of action of tran-
examic acid by evaluating brain images acquired before and 
after randomisation16. Brain images are primarily examined for 
evidence of intracranial haemorrhage and cerebral infarction. 
Patients who have a GCS score of 12 or less or intracranial bleed-
ing on a CT scan done before randomisation are eligible for 
inclusion. The results of the IBMS will be published when the 
CRASH-3 trial is complete. The IBMS protocol has been 
published and the associated statistical analysis plan will be 
published prior to completion of the CRASH-3 trial.
Data monitoring and interim analyses
An independent Data Monitoring Committee is responsible 
for reviewing the progress of the CRASH-3 trial, including 
recruitment, data quality, and main outcomes and safety data. 
The DMC has the responsibility for deciding whether, while 
randomisation is in progress, the unblinded results (or the 
unblinded results for a particular subgroup), should be revealed 
to the Trial Steering Committee. They will do this if, and only if, 
two conditions are satisfied: (1) The results provide proof beyond 
reasonable doubt that treatment is on balance either definitely 
harmful or definitely favourable for all, or for a particular cat-
egory of, participants in terms of the major outcome; and (2) The 
results, if revealed, would be expected to substantially change the 
prescribing patterns of clinicians who are already familiar with 
other trial results that exist. Exact criteria for “proof beyond 
reasonable doubt” are not, and cannot be, specified by a purely 
mathematical stopping rule, but they are strongly influenced 
by such rules. This is in agreement with the Peto-Haybittle 
stopping rule27 whereby an interim analysis of major endpoint 
would generally need to involve a difference between treatment 
and control of at least three standard errors to justify premature 
disclosure. An interim subgroup analysis would have to be even 
more extreme to justify disclosure. This rule has the advan-
tage that the exact number and timing of interim analyses need 
not be pre-specified. In summary, the stopping rules require 
extreme differences to justify premature disclosure and involve 
an appropriate combination of mathematical stopping rules and 
scientific judgment. To date, five interim analyses have been 
conducted by the Data Monitoring Committee with no recom-
mendation for early stopping. These analyses were conducted 
in June 2012, March 2014, July 2015, May 2016 and December 
2017, and involved the complete analysis of the un-blinded data 
as per the trial protocol. There was no change to the protocol as 
a result of the interim analyses and there are no more interim 
analyses planned. There are no interim analyses planned for 
the IBMS. The final analysis of the unblinded results will take 
place after recruitment is complete and the database is hardlocked.
Data management and analysis software
All trial data is managed in accord with the CRASH-3 trial 
Data Management Plan (DMP) (version 1.1) and stored in the 
Trial Master File. The DMP standard operating procedures are 
produced in conjunction with the London School of Hygiene 
and Tropical Medicine (LSHTM) policies and procedures, 
the Clinical Trials Unit working procedures, and regulatory 
requirements. The clinical database management system for 
CRASH-3 trial and IBMS was built to comply with ICH-GCP. 
The database was developed by Sealed Envelope Ltd (UK). 
In the CRASH-3 trial, data are collected at each participat-
ing site and transmitted directly to the Clinical Trials Unit via 
the database. Where there is poor internet connection, the paper 
CRFs can be sent by fax or via email. Data checks and cleaning 
are performed by the Clinical Trials Unit. Data items to be 
coded including Adverse Event term and terms used to describe 
‘other’ causes of death on the Outcome Form are coded 
using MedDRA Version 12. In the IBMS, the outcome data is 
directly uploaded onto an electronic database accessed at each 
sub-study site. The final database lock will take place at the 
end of the trial within three months from the time when the 
‘Last patient’ in the ‘Last follow-up’ has completed the trial. 
Data will be exported for statistical analysis using the most 
recent version of Stata [StataCorp LP, College Station, Texas, 
USA].
Dissemination of findings
The results of the CRASH-3 trial will be published in an estab-
lished peer-reviewed journal. At least one publication of the 
main trial results will be made. Links to the publication will 
be provided in all applicable trial registers. Dissemination of 
results to patients will take place via the media, trial website and 
relevant patient organizations. In addition, participants and their 
families will be made aware of the trial results if requested. 
Collaborating investigators will play a vital role in disseminat-
ing the results to colleagues and patients. The success of the trial 
will be dependent entirely upon the collaboration of the nurses 
and doctors in the participating hospitals and those who hold key 
responsibility for the trial. Hence, the credit for the study will 
be assigned to the key collaborator(s) from each participating 
site, as it is crucial that those taking credit for the work have 
actually carried it out. The results of the trial will be reported 
first to trial collaborators. As a large number of hospitals in many 
countries will contribute to this trial, individual countries or 
sites cannot restrict the publication of the manuscript relat-
ing to the outcomes of this trial. Anonymous data for this trial 
will be made available for free use at The Free Bank of Injury 
and emergency Research Data (freeBIRD) website. Following 
publication of the primary and secondary analyses detailed in 
this statistical analysis plan, the trial data will be made avail-
able via our data sharing portal - The Free Bank of Injury and 
emergency Research Data (freeBIRD) website. This will allow for 
maximum utilization of the data to improve patient care and 
advance medical knowledge.
Study status
The trial is currently recruiting patients and at the time of 
writing a total of 11,500 patients had been enrolled (target sample 
size 13,000).
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Discussion
This statistical analysis plan is an update to our previously 
published protocols. The main changes are: an increased 
sample size from 10,000 to 13,000 patients, and a change in the 
primary end point to death in hospital within 28 days of injury 
among patients randomised within 3 hours of injury but with a 
focus on very early treatment. We present our plan for the statis-
tical analyses in advance of the database lock and un-blinding to 
guard against data dependent analyses. The CRASH-3 trial should 
provide reliable evidence on the effect of tranexamic acid on 
death and disability in patients with TBI.
Data availability
No data are associated with this article.
Grant information
This work was supported by the Wellcome Trust [105439] through 
a Joint Global Health Trials Scheme in low-middle income 
countries Grant funded by the UK Government Department 
for International Development, UK Medical Research Council 
and Wellcome Trust [MR/M009211/1]. 
The CRASH-3 is fully funded by the Joint Global Health Trials 
Scheme in low-middle income countries Grant and by the National 
Institute for Health Research, Health Technology Assessment 
programme for the United Kingdom [14/190/01]. Funding for 
recruitment in the European Union and North America is pro-
vided by the London School of Hygiene and Tropical Medicine 
[EPNPBH61]. The IBMS is fully funded by the London School of 
Hygiene and Tropical Medicine [EPAA6020]. The design, man-
agement and interpretation of the CRASH-3 trial and IBMS are 
entirely independent of the manufacturers of tranexamic acid or 
the funders. Proof of all funding has been provided and reviewed 
on publication of the CRASH-3 trial and IBMS protocols15,16. 
The JP Moulton Charitable Trust (United Kingdom) 
is funding the run-in costs for the CRASH-3 trial and the 
recruitment of up to 500 patients.
The funders had no role in study design, data collection and 
analysis, decision to publish, or preparation of the manuscript.
Acknowledgements
The authors thank all patients and their families for their partici-
pation in the CRASH-3 trial. The authors thank all collaborating 
sites for their contribution to the CRASH-3 trial, and all funders 
for their financial support. The authors thank all staff in the 
Clinical Trials Unit at LSHTM who work in the administration, 
management and analysis of the CRASH-3 trial.
Full list of CRASH-3 collaborators is available as Supplementary 
File 2.
Supplementary material
Supplementary File 1: Trial entry form.
Click here to access the data.
Supplementary File 2: CRASH-3 trial personnel and collaborators.
Click here to access the data.
References
1. Peden M, McGee K, Sharma G: The injury chart book: A graphical overview 
of the global burden of injuries. Geneva: World Health Organization; 2002. 
Reference Source
2. Bruns J Jr, Hauser WA: The epidemiology of traumatic brain injury: a review. 
Epilepsia. 2003; 44(s10): 2–10.  
PubMed Abstract | Publisher Full Text 
3. Haagsma JA, Graetz N, Bolliger I, et al.: The global burden of injury: incidence, 
mortality, disability-adjusted life years and time trends from the Global Burden 
of Disease study 2013. Inj Prev. 2016; 22(1): 3–18.  
PubMed Abstract | Publisher Full Text | Free Full Text 
4. Perel P, Roberts I, Bouamra O, et al.: Intracranial bleeding in patients with 
traumatic brain injury: a prognostic study. BMC Emerg Med. 2009; 9: 15. 
PubMed Abstract | Publisher Full Text | Free Full Text 
5. Oertel M, Kelly DF, McArthur D, et al.: Progressive hemorrhage after head 
trauma: predictors and consequences of the evolving injury. J Neurosurg. 2002; 
96(1): 109–16.  
PubMed Abstract | Publisher Full Text 
6. Narayan RK, Maas AI, Servadei F, et al.: Progression of traumatic intracerebral 
hemorrhage: a prospective observational study. J Neurotrauma. 2008; 25(6): 
629–39.  
PubMed Abstract | Publisher Full Text 
7. Homnick A, Sifri Z, Yonclas P, et al.: The temporal course of intracranial 
haemorrhage progression: how long is observation necessary? Injury. 2012; 
43(12): 2122–5.  
PubMed Abstract | Publisher Full Text 
8. Harhangi BS, Kompanje EJ, Leebeek FW, et al.: Coagulation disorders after 
traumatic brain injury. Acta Neurochir (Wien). 2008; 150(2): 165–75; discussion 75. 
PubMed Abstract | Publisher Full Text 
9. Bayir A, Kalkan E, Koçak S, et al.: Fibrinolytic markers and neurologic outcome 
in traumatic brain injury. Neurol India. 2006; 54(4): 363–5.  
PubMed Abstract | Publisher Full Text 
10. Ker K, Prieto-Merino D, Roberts I: Systematic review, meta-analysis and meta-
regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 
2013; 100(10): 1271–9.  
PubMed Abstract | Publisher Full Text 
11. CRASH-2 Collaborators, Shakur H, Roberts I, et al.: Effects of tranexamic acid 
Page 10 of 18
Wellcome Open Research 2018, 3:86 Last updated: 26 SEP 2018
on death, vascular occlusive events, and blood transfusion in trauma patients 
with significant haemorrhage (CRASH-2): a randomised, placebo-controlled 
trial. Lancet. 2010; 376(9734): 23–32.  
PubMed Abstract | Publisher Full Text 
12. CRASH-2 Collaborators, Roberts I, Shakur H, et al.: The importance of early 
treatment with tranexamic acid in bleeding trauma patients: an exploratory 
analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771): 
1096–101, 101 e1-2.  
PubMed Abstract | Publisher Full Text 
13. WOMAN Trial Collaborators: Effect of early tranexamic acid administration on 
mortality, hysterectomy, and other morbidities in women with post-partum 
haemorrhage (WOMAN): an international, randomised, double-blind, placebo-
controlled trial. Lancet. 2017; 389(10084): 2105–16.  
PubMed Abstract | Publisher Full Text | Free Full Text 
14. Gayet-Ageron A, Prieto-Merino D, Ker K, et al.: Effect of treatment delay on the 
effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a 
meta-analysis of individual patient-level data from 40 138 bleeding patients. 
Lancet. 2018; 391(10116): 125–132.  
PubMed Abstract | Publisher Full Text | Free Full Text 
15. Dewan Y, Komolafe EO, Mejia-Mantilla JH, et al.: CRASH-3 - tranexamic acid 
for the treatment of significant traumatic brain injury: study protocol for an 
international randomized, double-blind, placebo-controlled trial. Trials. 2012; 13: 87. 
PubMed Abstract | Publisher Full Text | Free Full Text 
16. Mahmood A, Roberts I, Shakur H: A nested mechanistic sub-study into the 
effect of tranexamic acid versus placebo on intracranial haemorrhage and 
cerebral ischaemia in isolated traumatic brain injury: study protocol for a 
randomised controlled trial (CRASH-3 Trial Intracranial Bleeding Mechanistic 
Sub-Study [CRASH-3 IBMS]). Trials. 2017; 18(1): 330.  
PubMed Abstract | Publisher Full Text | Free Full Text 
17. Roberts I, Prieto-Merino D, Manno D: Mechanism of action of tranexamic acid in 
bleeding trauma patients: an exploratory analysis of data from the CRASH-2 
trial. Crit Care. 2014; 18(6): 685.  
PubMed Abstract | Publisher Full Text | Free Full Text 
18. Raza I, Davenport R, Rourke C, et al.: The incidence and magnitude of fibrinolytic 
activation in trauma patients. J Thromb Haemost. 2013; 11(2): 307–14.  
PubMed Abstract | Publisher Full Text 
19. Liras IN, Cotton BA, Cardenas JC, et al.: Prevalence and impact of admission 
hyperfibrinolysis in severely injured pediatric trauma patients. Surgery. 2015; 
158(3): 812–8.  
PubMed Abstract | Publisher Full Text 
20. Chapman MP, Moore EE, Moore HB, et al.: Overwhelming tPA release, not PAI-1 
degradation, is responsible for hyperfibrinolysis in severely injured trauma 
patients. J Trauma Acute Care Surg. 2016; 80(1): 16–23; discussion 23–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
21. Wu X, Darlington DN, Cap AP: Procoagulant and fibrinolytic activity after 
polytrauma in rat. Am J Physiol Regul Integr Comp Physiol. 2016; 310(4): R323–9. 
PubMed Abstract | Publisher Full Text | Free Full Text 
22. Moore EE, Moore HB, Gonzalez E, et al.: Postinjury fibrinolysis shutdown: 
Rationale for selective tranexamic acid. J Trauma Acute Care Surg. 2015;  
78(6 Suppl 1): S65–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
23. Epstein DS, Mitra B, O'Reilly G, et al.: Acute traumatic coagulopathy in the 
setting of isolated traumatic brain injury: a systematic review and meta-
analysis. Injury. 2014; 45(5): 819–24.  
PubMed Abstract | Publisher Full Text 
24. Abdelmalik PA, Boorman DW, Tracy J, et al.: Acute Traumatic Coagulopathy 
Accompanying Isolated Traumatic Brain Injury is Associated with Worse 
Long-Term Functional and Cognitive Outcomes. Neurocritical Care. 2016; 24(3): 
361–70.  
PubMed Abstract | Publisher Full Text 
25. Folkerson LE, Sloan D, Cotton BA, et al.: Predicting progressive hemorrhagic 
injury from isolated traumatic brain injury and coagulation. Surgery. 2015; 
158(3): 655–61.  
PubMed Abstract | Publisher Full Text 
26. Nakae R, Yokobori S, Takayama Y, et al.: Age-related differences in fibrinolytic 
parameters in patients with acute traumatic brain injury. Surg Neurol Int. 2017; 
8: 214.  
PubMed Abstract | Free Full Text 
27. Haybittle JL: Repeated assessment of results in clinical trials of cancer 
treatment. Br J Radiol. 1971; 44(526): 793–7.  
PubMed Abstract | Publisher Full Text 
Page 11 of 18
Wellcome Open Research 2018, 3:86 Last updated: 26 SEP 2018
 Open Peer Review
    Current Referee Status:
Version 1
 21 September 2018Referee Report
doi:10.21956/wellcomeopenres.16009.r33536
 Susanne May
The Clinical Trials Center, Department of Biostatistics, University of Washington, Seattle, WA, USA
Comments: (page numbers refer to the pdf version)
Abstract
One of the major reasons for the change is the focus on patients receiving treatment within 3 hours of
injury and the sample size was modified to accommodate this. It is unclear from the abstract though what
the (new) target enrolment number is for those patients that receive treatment within 3 hours. This also
does not seem to be clear from the text. There should either be a mentioning of the revised target sample
size for those who receive treatment within three hours or a justification why that is not given.
It would be helpful to state in the abstract the timeframe for the mortality outcomes for the secondary
outcomes (are they the same as for the primary?).
It is unclear (but might difficult to explain concisely) what is meant by subgroup .. stratified by “baseline
risk”. How is baseline risk defined?
 
Generally
In the emergency setting it is difficult to imagine that the time from injury to treatment can be measured
exactly. It would be helpful to discuss this at least to some degree and to consider adding the word
“estimated” if that is judged to be appropriate.
Another subject that would be good to provide a little further information (unless it is in one of the
referenced docs) is how “discharged alive” is defined. E.g. what about discharge to hospice?
 
 
“list of abbreviations section” SUSARs: Suspected unexpected rather than Suspected unsuspected.
Regarding page 3 left column at the bottom: would be good to mention “blinded” here as well.
Regarding section Randomisation and masking: might be helpful to mention the TXA dose here as well.
Regarding section “sample size”, I don’t understand why the updated sample size calculations can not be
provided. If there is a reason for why, the reason should be given/described.
Regarding section “Baseline characteristics” At the end of the paragraph it is indicated that baseline
characteristics of each group will be described with frequencies and percentages. Is that sufficient? How
about for continuous variables? Or are they all dichotomized or divided into categories?
Regarding page 5 left column second paragraph, “however…” it seems that if this is the primary
justification, the article was published in 2011, why wait until 2016 to make the change? Just an additional
comment regarding the reason for the time lapse would be good.
Regarding Primary analysis: If I am not mistaken, two measures (relative and absolute risks) are
suggested for the primary analysis. This can lead to multiple comparison issues and what would be done
if the results were contradictory? It would be best to choose one specific analysis for the primary analysis
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 suggested for the primary analysis. This can lead to multiple comparison issues and what would be done
if the results were contradictory? It would be best to choose one specific analysis for the primary analysis
and suggest the other one as secondary.
Regarding Missing data: Is there any evidence/data to suggest that patients (or family members) might
withdraw consent?
Regarding Figure 1: Did I miss it, or what were the data the graphs are based on? Where do these data
for the graphs come from?
Regarding secondary outcomes: … “will examine the effect of TXA on head injury deaths within 48 hours
and 7 days of randomisation”. This could be problematic, if TXA were to contribute to more deaths within
the first 48 hours.
Regarding section “disability”: at what time point(s) are those disability measures taken. Why are both
parametric and non-parametric tests proposed? What would be the conclusions if the test disagree? How
would adjustments be made for multiple comparisons if any?
Regarding section: “Neurosurgical intervention for intracranial haemorrhage” why aren’t specific statistical
test proposed in other sections except here (t-test)?
Regarding “Other analysis: to be reported in separate publications” Excluding early deaths is said to allow
evaluation of treatment effect “without this null bias”. But if TXA has some effect on early patient survival,
the result might be that patients on TXA are sicker if early deaths are excluded.
Regarding p8 left column paragraph starting with “the primary outcome…”: “missing values will be
replaced by the mean of the observed data” such single imputation approach will lead to underestimating
the variability in the data and depending on the actual amount of missingness (even though the authors
assume it is going to be a small amount) can lead to serious bias in estimating the variability in the data
and should be avoided.
Regarding p8 right column: “However, we hypothesise that the risk reduction with tranexamic acid would
be greatest in patients at low risk of death since a smaller proportion of these patients will have
un-survivable TBI”. This depends on how “low risk” is defined, as in this population one might expect a
certain percentage of patients who get better without even needing TXA (thus at low risk, e.g. patients
who are intoxicated and have a TBI, it is very difficult to tell at the time of treatment initiation how severely
they are actually injured and whether or not they would need any TXA).
Regarding Analysis 3: censoring deaths for length of ICU stay: similar to excluding early deaths,
censoring of deaths for this analysis could seriously bias the results as “censoring” in the analysis typically
carries the assumption of “independent censoring” which is unlikely to be true. Also, if TXA were to have
any beneficial impact on early survival this might result in a longer ICU stay on average for this group and
would be problematic in this analysis.
Regarding line 4 left column p9: write out abbreviation TSC and line -13 write out abbreviation PHP.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Partly
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
No source data required
Are the conclusions about the method and its performance adequately supported by the
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 Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 I am the Principal Investigator of another trial examining the effect of TXA in TBI.Competing Interests:
This might (or might not) be considered a competing interest by readers.
Referee Expertise: Biostatistics
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
 20 August 2018Referee Report
doi:10.21956/wellcomeopenres.16009.r33535
  ,     Anna Teresa Mazzeo Deepak Kumar Gupta
 Department of Anaesthesia and Intensive Care, Università di Torino, Torino, 10126, Italy
  Department of Neurosurgery, Neurosciences Centre, All India Institute of Medical Sciences, Delh
(AIIMS), New Delhi, Delhi, India
Early administration of TXA ( tranexamic acid) within 3 hrs safely reduced the risk of death in bleeding
trauma patients and was found to be highly cost-effective in CRASH 2 study of 20211 patients [ which
included polytrauma subjects with traumatic brain injury also] . CRASH-3 study aims to evaluate the
effectiveness and safety of TXA in the treatments of isolated brain injury patients. It is believed that early
administration of tranexamic acid in TBI patients might limit intracranial bleeding, reducing death and
disability. 
Present study [CRASH-3] now plans to recruit 13000 TBI patients [ Sample size increased by 3000  to get
enough patients within 3 hours of injury instead of earlier proposed 8 hrs ] for randomisation to tranexamic
acid or matching placebo in addition to usual care. The primary outcome is head injury death in hospital
within 28 days of injury for patients treated within 3 hours of injury.  Recruitment is unlikely to be an issue
[due to recent  protocol update to include patients within 3 hours of injury] as 11500 patients have already
been included in the study [hoping that all/majority of them were randomised and treated within 3 hours of
injury]. Null hypothesis of homogeneity is not required in this study due to available evidence from
CRASH 2 study on the same drug.
Worldwide, about 50 million people have a TBI each year, and it is estimated that about half the world’s
population will have one or more TBIs over their lifetime. Approximately 50% of trauma deaths are likely
related to TBI which would imply that about one TBI-related death occurs every 3 minutes in some nations
(India). Many epidemiological studies based on comparative effectiveness research model (CER) are
currently underway/completed recruitments to better characterize TBI and to identify effective clinical
interventions for TBI care. Centre TBI for adults and ADAPT for children have completed recruitments of
over 5000 ( Adults) and 1000 ( children) already and their results are likely to throw further light on our
understanding of traumatic brain injuries .
 
In- hospital  28 days mortality end point analysis as study drug effect may not translate to long term
outcome in TBI subjects for various reasons.We documented influence of achieving early ICU adherence
to  head trauma guidelines with significantly lower in-hospital mortality in comparative study of two
centres. Although long-term outcomes generally improved, patients discharged with favourable GOS
1 2
1
2
1
2
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 centres. Although long-term outcomes generally improved, patients discharged with favourable GOS
score often deteriorated at home thereby implying influence of need of rehabilitation care for TBI subjects
[ CHIRAG Study] .
 
TBI population is quite heterogenous both in terms of mechanism of injury and in prehospital /in-hospital
treatment delays.  It may be noted that in some of developing nations prehospital services are still lacking
for most of TBI subjects. Loss of follow up data margin of 1% sounds a bit too optimistic as some of TBI
subjects who live in far off catchments areas may not be available for follow ups after initial discharge from
hospital. 
 
Current statistical analysis plan with increased patient number within three hours of injury and  primary
end point of death in hospital within 28 days of injury amongst randomized looks fine and is likely to
provide evidence on effect of this drug on death and disability in patients with TBI. However, for
developing nations where prehospital infrastructure is still lacking, it will be worthwhile looking at results of
this drug or patients treated within 3-8 hours of injury too.
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Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
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 If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Neurotrauma
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
 07 August 2018Referee Report
doi:10.21956/wellcomeopenres.16009.r33537
 Shahriar Zehtabchi
Department of Emergency Medicine, State University of New York, Downstate Medical Center, Brooklyn,
NY, USA
This manuscript outlines the detail of the revised statistical analysis plan for CRASH-3 trial. The trial is
being conducted to assess the impact of administration of tranexamic acid on the survival of patients with
traumatic brain injury. The study design has been adjusted to improve the likelihood of identifying the
benefit if it exists. This adjustment includes enrolling within a narrower window after head injury. This
adjustment is justified by studies that proved the most benefit from TXA within the first 3 hours of brain
injury. The investigators had to adjust  (increase) the sample size to maintain the study power at the
pre-designed level.
The details of the trial objectives, trial outcomes, and the methodology as well as the statistical analysis
plan are well described. 
Minor:
- Page 5, under the section Primary Outcome, the authors state: "......The results showed that immediate
treatment improved survival by more than 70% (OR 1.72, 95% CI 1.42-2.10)"  The number 70% is
obviously the relative risk reduction. It would be more helpful for the readers to know the absolute risk
reduction/difference. I was not able to calculate the absolute risk difference from the referenced original
trial either.
- Small trails published on this topic have measured the effect of TXA on the size of hematoma as well (in
those with documented brain hematoma). This is clearly not a patient-centered outcome. However, it
would have been interesting for the readers to know why the investigators do not wish to measure this
outcome.
Is the rationale for developing the new method (or application) clearly explained?
Yes
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 Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
Referee Expertise: Neurological emergencies
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 25 July 2018Referee Report
doi:10.21956/wellcomeopenres.16009.r33534
   Paul S. Myles
Department of Anaesthesia and Perioperative Medicine, Alfred Hospital, Monash University, Melbourne,
Vic, Australia
Excellent overview and justification, and highly relevant to eventual interpretation of the results
and implementation. There are now consistent data showing a differential effect of TxA according to the
timing of injury and administration.
Although all-cause mortality is important and robust, disability-free survival (from the DRS) should if
possible also be estimated.
There are some data  suggesting that TxA may reduce infection risk, and so both mortality and other
outcomes have pick this up (as opposed to it being "diluted").
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
Page 17 of 18
Wellcome Open Research 2018, 3:86 Last updated: 26 SEP 2018
 Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 I have been invited to undertake an IPD meta-analysis with Ian Roberts. My reportCompeting Interests:
was not influenced by my relationship with the author.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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